Recently, Shenzhen Baitewei Medical Technology Co., Ltd. (“Baitewei Medical”) announced the completion of a nearly 100 million yuan Series B financing round. The round was led by Tasly Capital, with Qinzhi Capital as a co-investor, and Vision Capital acted as the exclusive financial advisor. The proceeds will mainly be used for new product R&D, production base construction and market expansion, accelerating the company’s layout of innovative products in peripheral vascular intervention and heart failure.

Building a peripheral intervention product matrix, achieving domestic breakthroughs in multiple devices

In the field of peripheral vascular intervention, Baitewei has established a full product matrix covering “thromboreduction + thrombectomy + access”, with multiple technologies at a leading domestic level. Several devices have achieved domestic breakthroughs and successfully obtained market approval. Meanwhile, a number of additional innovative products are in the clinical application and registration stage, forming a full-cycle and sustainable product R&D and commercialization system.

The peripheral venous thrombectomy system independently developed by Baitewei is the only domestic product in its category approved for the Special Review Green Channel for Innovative Medical Devices. Led by Lu Xinwu, Director of Vascular Surgery at Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the product has completed domestic multi-center registration clinical trials and is pending domestic approval. In addition, the company’s pulmonary artery thrombectomy system, approved in China in 2025, is the only self-expanding stent-based thrombectomy system in China, with a design directly comparable to second-generation foreign competing products and full independent intellectual property rights. The company is also actively laying out products such as arterial thromboreduction, aiming to build the leading domestic brand for physical thromboreduction in peripheral blood vessels.

Focusing on the blue-ocean heart failure market, expected to build China’s first implant-free atrial shunt system

Baitewei targets heart failure, known as the "final frontier" of cardiovascular diseases, and develops comprehensive device solutions for heart failure and syndromes induced by its complications, with a key focus on atrial shunt systems to fill gaps in related domestic treatment fields. Currently, only a few companies worldwide are engaged in the atrial shunt sector. Baitewei is among the first enterprises in China to enter the clinical stage and is expected to launch China’s first atrial shunt system and the world’s first implant-free atrial shunt system. Meanwhile, the company is continuously expanding its product line around heart failure diagnosis and treatment, developing a number of innovative devices to build a complete solution covering diagnosis, treatment and monitoring.

Relying on its self-developed process platform and cross-border technology integration capabilities, Baitewei has established a significant first-mover advantage in peripheral intervention and heart failure. The company will continue to launch high-quality new products, steadily advance the product commercialization process, continuously enrich the product matrix and improve market supply capacity, meet market and user needs with a steady stream of innovative achievements, and provide solid support for the long-term and steady development of the business.

Statement by Mr. Long Han, Founder of Baitewei Medical

“We would like to express our gratitude for the trust and support of all shareholders and investors! Baitewei will, as always, carry out independent innovative R&D based on clinical needs and build a differentiated product matrix portfolio. With technological innovation as the core driving force, we will accelerate product implementation and commercialization through industry-university-research-hospital collaboration.

With the successful completion of this round of financing, the company will accelerate the operation of its new industrial base, Zhongshan Baitewei. Meanwhile, the company’s domestic sales headquarters in Beijing has been established, all of which will lay a solid foundation for Baitewei’s next five-year development period. Looking forward, we hope that more independently innovative devices of Baitewei will enter clinical application, so that domestic medical and technological achievements can benefit a large number of patients and contribute to the high-quality development of the domestic medical industry.”